

Zhao-Shi Bao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9551662/publications.pdf>

Version: 2024-02-01

20
papers

676
citations

932766

10
h-index

839053

18
g-index

20
all docs

20
docs citations

20
times ranked

1218
citing authors

#	ARTICLE	IF	CITATIONS
1	RNA-seq of 272 gliomas revealed a novel, recurrent <i>PTPRZ1-MET</i> fusion transcript in secondary glioblastomas. <i>Genome Research</i> , 2014, 24, 1765-1773.	2.4	316
2	Prognostic Value of a Nine-Gene Signature in Glioma Patients Based on mRNA Expression Profiling. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 112-118.	1.9	83
3	Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. <i>Oncotarget</i> , 2015, 6, 36643-36651.	0.8	39
4	Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma. <i>Frontiers in Immunology</i> , 2019, 10, 1756.	2.2	35
5	Overexpression of Paxillin Correlates with Tumor Progression and Predicts Poor Survival in Glioblastoma. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 69-75.	1.9	32
6	PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. <i>Oncotarget</i> , 2019, 8, e1541535.	2.1	32
7	Prognostic Correlation of Autophagy-Related Gene Expression-Based Risk Signature in Patients with Glioblastoma. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 95-107.	1.0	29
8	Whole-Genome mRNA Expression Profiling Identifies Functional and Prognostic Signatures in Patients with Mesenchymal Glioblastoma Multiforme. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 714-720.	1.9	24
9	Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions. <i>FEBS Letters</i> , 2015, 589, 1437-1443.	1.3	20
10	MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas. , 2021, 9, e002451.		13
11	Risk factors and the prognosis of sexual dysfunction in male patients with pituitary adenomas: a multivariate analysis. <i>Asian Journal of Andrology</i> , 2018, 20, 43.	0.8	11
12	Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas. <i>Oncotarget</i> , 2016, 7, 45005-45014.	0.8	10
13	Clinical and Molecular Characterization of Incidentally Discovered Lower-Grade Gliomas with Enrichment of Aerobic Respiration. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9533-9542.	1.0	8
14	Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 953-966.	2.0	8
15	Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases. <i>Cancer Science</i> , 2022, 113, 796-801.	1.7	7
16	Mutation and Copy Number Alterations Analysis of KIF23 in Glioma. <i>Frontiers in Genetics</i> , 2021, 12, 646929.	1.1	6
17	Predicting the likelihood of postoperative seizure status based on mRNA sequencing in low-grade gliomas. <i>Future Oncology</i> , 2018, 14, 545-552.	1.1	1
18	Comprehensive analysis of multi-omics data of recurrent gliomas identifies a recurrence-related signature as a novel prognostic marker. <i>American Journal of Cancer Research</i> , 2021, 11, 1226-1246.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	1
20	Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme. <i>Oncology Letters</i> , 2020, 20, 187.	0.8	0